A new method using IGC was developed for quantification of indomethacin surface amorphization induced by milling. It was found that the surface amorphization rate is an order of magnitude higher than the mass amorphization rate as obtained by DSC.
COBISS.SI-ID: 2733937
The aim of the study was to evaluate potential long-term toxicity after long-term exposure at short-term safe concentrations. It was established that long-term exposure of the cells to the short-term safe concentration of ZnO nanoparticles causes decreased mitochondrial activity, changes in cell morphology and disturbances in the cell cycle. On the other hand, cell exposure to TiO2 nanoparticles does not demonstrate such effects. Both types of nanoparticles after long-term exposure provoke increased number of intercellular nanotubes, which may indicate transformation of normal to tumor cells.
COBISS.SI-ID: 2842481
This work describes the first experimental confirmation of a livelong hypothesis about the mechanism of an undesired interaction between an important group of antibacterials (fluoroquinolones) and metal ions from concomitantly administered drugs or food. We have shown in biorelevant "in vitro" conditions that ciprofloxacin permeability through the small intestinal mucosa is decreased in the presence of metal cations and have also proven that the complexes of ciprofloxacin and aluminum do not permeate through the small intestinal mucosa in analytically detectable amounts.
COBISS.SI-ID: 2854257
Population pharmacokinetic modeling was used to characterize the metabolism of risperidone in patients with schizophrenia. In comparison to the patients with CYP2D6*1/*1 genotype, plasma concentration of risperidone active moiety was 3.3- and 1.6-fold higher in poor and intermediate metabolizers, respectively. Additionally, active moiety concentration was higher in patients with dystonia and parkinsonism. The results imply the potential role of CYP2D6 genotyping in personalizing risperidone therapy in patients with schizophrenia to reduce the incidence of adverse extrapyramidal symptoms.
COBISS.SI-ID: 2824049
Human papillomavirus (HPV) vaccination alongside screening compared to screening alone was associated with an incremental cost-effectiveness ratio of 23,178 EUR per QALY and 54,536 EUR per LYG at the discounting rate of 5%. According to the cost-effectiveness thresholds of 30,000 EUR per QALY which was adopted by the Health Council in Slovenia, HPV vaccination alongside screening programme can be regarded as cost-effective. However, cost-effectiveness of HPV vaccination would become questionable in case a booster dose was needed to provide lifetime protection.
COBISS.SI-ID: 2834033